TNF-α inhibitors reduce the systemic inflammation and improve the endothelial function, decreasing the risk of pulmonary arterial hypertension progression and of acute cardiovascular and/or cerebrovascular events [14]. Here, TNF is linked to pulmonary arterial hypertension.